18 janv. 2021
Theranexus reported ongoing progress on its THN102 and BBDF-101 programs, €11.2m in cash at 31 December 2020, and the implementation of a new €8.4m equity line with IRIS to extend its funding visibility and support BBDF-101 development.
Lyon, january 18 2021 - Theranexus is advancing partnership discussions for THN102 in Parkinson’s disease and preparing BBDF-101 for an IND filing and clinical trial launch in Batten disease, supported by a year-end 2020 cash position of €11.2m. To secure about 18 months of financial visibility while keeping negotiating power on THN102, the company set up a 12-month equity line of up to €8.4m with IRIS via warrants and bonds convertible into new shares, implying potential dilution for existing shareholders upon conversion.
Download Theranexus press release